Roots Analysis has done a detailedstudy on ContinuousManufacturing Market (Small Molecules andBiologics), 2020 – 2030. covering key aspects of the industry and identifying futuregrowth opportunities.
To order this 310+page report, which features 110+ figures and 200+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Key Market Insights
§ Eminentrepresentatives from prominent contract service provider companies /organizations are both optimistic and cautious regarding the rising interest incontinuous flow technologies, and its adoption
§ Over 60 companiesacross the globe claim to manufacture drug products / drug substances using thecontinuous manufacturing technique, either for in-house requirements or forcontract service engagements
§ The market landscapefeatures the presence of several well-established players, most of which claimto manufacture small molecules via the continuous technique, and are based inthe developed geographies
§ Companies have established continuous drug manufacturing facilities fordiverse types of dosage forms in various geographies; Europe and North Americahave emerged as the key hubs for these facilities
§ Several patents havebeen filed / granted specifically related to continuous manufacturing ofpharmaceutical substances, both industry and non-industry players are activelyinvolved in such efforts
§ Organizations havealso extended financial support to aid the research efforts being put byvarious stakeholders in this domain; the current focus is on investigation ofcontinuous manufacturing technologies
§ Over time, there has been a lot of activity in this arena, including theestablishment of several partnerships and investments in capability andcapacity expansions and new facilities worldwide
§ Most of thecontinuous manufacturing capacity belongs to established companies (in-housemanufacturers and CMOs), accounting for over 70% of the available capacityacross various geographies
§ Involvement of various other stakeholders including continuous equipmentproviders and modular facility providers is likely to revolutionize the overallmanufacturing domain
§ As the adoption ofcontinuous manufacturing technologies increases, the market is likely towitness significant growth; in the short term, majority of service-basedrevenues is likely to come from drug product related projects
For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Table of Contents
TABLE OF CONTENTS
1. PREFACE
1.1. Scope ofthe Report
1.2. ResearchMethodology
1.3. ChapterOutlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. HistoricalEvolution of Continuous Manufacturing
3.3. ContinuousManufacturing in the Pharmaceutical Industry
3.3.1. RegulatoryLandscape
3.3.2. EarlyAdopters of Continuous Manufacturing
3.3.3. AnticipatedShift to Continuous Manufacturing
3.3.4. Advantagesof Continuous Manufacturing
3.3.5. KeyChallenges Associated with Continuous Manufacturing
3.3.6. FuturePerspectives
4. MARKETLANDSCAPE
4.1. ChapterOverview
4.2. Companieswith Expertise in Continuous Manufacturing: Overall Market Landscape
4.2.1. Analysis byYear of Establishment
4.2.2. Analysis byCompany Size
4.2.3. Analysis byPurpose of Manufacturing
4.2.4. Analysis byScale of Operation
4.2.5. Analysis byLocation of Headquarters
4.2.6. Analysis byLocation of Continuous Manufacturing Facilities
4.2.7. Analysis byType of Drug Molecule
4.2.8. Analysis byType of Continuous Manufacturing Related Service
4.2.9. Analysis byType of Dosage Form
4.2.10. Heat Map:Analysis by Company Size and Location of Headquarters
4.2.11. Informationon Production Capacity
4.2.12. LogoLandscape: Analysis by Year of Establishment and Company Size
4.2.13. Grid Representation: Analysis by Scale ofOperation, Type of Continuous Manufacturing Related Service and Type of DosageForm
4.2.14. Geographical Map: Analysis by Location of ContinuousManufacturing Facilities and Type of Drug Molecule
5. COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN NORTH AMERICA: PROFILES
5.1. ChapterOverview
5.2. AbbVieContract Manufacturing
5.2.1. CompanyOverview
5.2.2. ServicePortfolio
5.2.3. ContinuousManufacturing Capabilities and Facilities
5.2.4. RecentDevelopments and Future Outlook
5.3. Cambrex
5.3.1. CompanyOverview
5.3.2. ServicePortfolio
5.3.3. ContinuousManufacturing Capabilities and Facilities
5.3.4. Recent Developmentsand Future Outlook
5.4. Patheon
5.4.1. CompanyOverview
5.4.2. ServicePortfolio
5.4.3. ContinuousManufacturing Capabilities and Facilities
5.4.4. RecentDevelopments and Future Outlook
5.5. SK biotek
5.5.1. CompanyOverview
5.5.2. ServicePortfolio
5.5.3. ContinuousManufacturing Capabilities and Facilities
5.5.4. RecentDevelopments and Future Outlook
6. COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN EUROPE: PROFILES
6.1. ChapterOverview
6.2. AjinomotoBio-Pharma Services
6.2.1. CompanyOverview
6.2.2. ServicePortfolio
6.2.3. ContinuousManufacturing Capabilities and Facilities
6.2.4. RecentDevelopments and Future Outlook
6.3. Almac
6.3.1. CompanyOverview
6.3.2. ServicePortfolio
6.3.3. ContinuousManufacturing Capabilities and Facilities
6.3.4. RecentDevelopments and Future Outlook
6.4. BoehringerIngelheim BioXcellence™
6.4.1. CompanyOverview
6.4.2. ServicePortfolio
6.4.3. ContinuousManufacturing Capabilities and Facilities
6.4.4. Recent Developmentsand Future Outlook
6.5. CordonPharma
6.5.1. CompanyOverview
6.5.2. ServicePortfolio
6.5.3. ContinuousManufacturing Capabilities and Facilities
6.5.4. RecentDevelopments and Future Outlook
6.6. Hovione
6.6.1. CompanyOverview
6.6.2. ServicePortfolio
6.6.3. ContinuousManufacturing Capabilities and Facilities
6.6.4. RecentDevelopments and Future Outlook
6.7. Lonza
6.7.1. CompanyOverview
6.7.2. ServicePortfolio
6.7.3. ContinuousManufacturing Capabilities and Facilities
6.7.4. RecentDevelopments and Future Outlook
7. COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. ChapterOverview
7.2. Kaneka
7.2.1. CompanyOverview
7.2.2. ServicePortfolio
7.2.3. ContinuousManufacturing Capabilities and Facilities
7.2.4. RecentDevelopments and Future Outlook
7.3. WuXi AppTec
7.3.1. CompanyOverview
7.3.2. ServicePortfolio
7.3.3. ContinuousManufacturing Capabilities and Facilities
7.3.4. RecentDevelopments and Future Outlook
8. RECENT PARTNERSHIPSAND COLLABORATIONS
8.1. ChapterOverview
8.2. PartnershipModels
8.3. List ofPartnerships and Collaborations
8.3.1. Analysis byYear of Partnership
8.3.2. Analysis byType of Partnership
8.3.3. Analysis byScale of Operation
8.3.4. Analysis byType of Drug Molecule
8.3.5. Analysis byType of Continuous Manufacturing Related Service
8.3.6. Analysis byType of Dosage Form
8.3.7. Most ActivePlayers: Analysis by Number of Partnerships
8.3.8. RegionalAnalysis
8.3.8.1. Intercontinentaland Intracontinental Agreements
9. RECENTEXPANSIONS
9.1. ChapterOverview
9.2. RecentExpansions
9.2.1. Analysis byYear of Expansion
9.2.2. Analysis byType of Expansion
9.2.3. Analysis byExpanded Scale of Expansion
9.2.4. Analysis byType of Drug Molecule
9.2.5. Analysis byType of Continuous Manufacturing Related Service
9.2.6. Analysis byType of Dosage Form
9.2.7. Most ActivePlayers: Analysis by Number of Expansions
9.2.8. RegionalAnalysis
9.2.8.1. Analysis byLocation of Expansion Project
10. CAPACITYANALYSIS
10.1. ChapterOverview
10.2. Assumptionsand Methodology
10.3. Global,Continuous Manufacturing Capacity for Small Molecule APIs
10.3.1. Analysis byCompany Size
10.3.2. Analysis byPurpose of Manufacturing
10.3.3. Analysis byScale of Operation
10.3.4. Analysis byLocation of Headquarters
10.3.4. Analysis byLocation of Continuous Manufacturing Facilities
10.4. Global,Continuous Manufacturing Capacity for Small Molecule End Products
10.4.1. Analysis byCompany Size
10.4.2. Analysis byPurpose of Manufacturing
10.4.3. Analysis byScale of Operation
10.4.4. Analysis byLocation of Headquarters
10.4.5. Analysis byLocation of Continuous Manufacturing Facilities
10.5. Global,Continuous Manufacturing Capacity for Biologic
10.5.1. Analysis byCompany Size
10.5.2. Analysis byPurpose of Manufacturing
10.5.3. Analysis byScale of Operation
10.5.4. Analysis byLocation of Headquarters
10.5.5. Analysis byLocation of Continuous Manufacturing Facilities
11. ACADEMICGRANT ANALYSIS
11.1. ChapterOverview
11.2. Scope andMethodology
11.3. ContinuousManufacturing: List of Academic Grants
11.3.1. Analysis byNumber of Grants
11.3.2. Analysis byActivity Code
11.3.3. Analysis byGrant Amount
11.3.4. Analysis by FocusArea
11.3.5. Analysis bySupport Period
11.3.6 PopularRecipient Organizations: Analysis by Number of Grants
11.3.7 Analysis byType of Recipient Organization
11.3.8. Analysis byFunding Institute Centre
11.3.9. Analysis byFunding Mechanism
11.3.10. Prominent Program Officers: Analysis by Number ofGrants
12. PATENTANALYSIS
12.1. ChapterOverview
12.2. Scope andMethodology
12.3. ContinuousManufacturing: Patent Analysis
12.3.1. Analysis byPublication Year
12.3.2. Analysis byGeography
12.3.3. Analysis byCPC Symbols
12.3.4. EmergingFocus Areas
12.3.5. Analysis byType of Applicant
12.3.6. LeadingPlayers: Analysis by Number of Patents
12.3.7. ContinuousManufacturing: Three-Dimensional Bubble Analysis
12.3.8. ContinuousManufacturing: Patent Valuation Analysis
12.3.8.1. Leading Patents: Information by Number ofCitations
13. INITIATIVES OF COMPANIES WITH IN-HOUSECONTINUOUS MANUFACTURING CAPABILITIES
13.1. ChapterOverview
13.2. ContinuousManufacturing Initiatives of Leading Companies
13.2.1. AbbVie
13.2.1.1. Partnered Initiatives
13.2.1.2 In-House Initiatives
13.2.2. Amgen
13.2.2.1. Partnered Initiatives
13.2.2.2. In-House Initiatives
13.2.3. Bristol-MyersSquibb
13.2.3.1. Partnered Initiatives
13.2.3.2. In-House Initiatives
13.2.4. GlaxoSmithKline
13.2.4.1. Partnered Initiatives
13.2.4.2. In-House Initiatives
13.2.5. Merck
13.2.5.1. Partnered Initiatives
13.2.5.2. In-House Initiatives
13.2.6. Novartis
13.2.6.1. Partnered Initiatives
13.2.6.2. In-House Initiatives
13.2.7. Pfizer
13.2.7.1. Partnered Initiatives
13.2.7.2. In-House Initiatives
13.2.8. Roche
13.2.8.1. Partnered Initiatives
13.2.8.2. In-House Initiatives
13.2.9. Sanofi
13.2.9.1. Partnered Initiatives
13.2.9.2. In-House Initiatives
14. CASE STUDY:MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
14.1. ChapterOverview
14.2. HistoricalBackground
14.3. Concept ofModularization
14.3.1. Types ofModules
14.3.2. ModularConstruction Process
14.4. ModularConstruction in the Pharmaceutical Industry
14.4.1. Advantages ofModular Construction in the Pharmaceutical Industry
14.5. ModularFacility Manufacturers
14.5.1. Distributionby Industry Served
14.5.2. Distributionby Geography
14.5.3. ModularProjects Executed / Undertaken
14.6. ModularPharmaceutical Cleanrooms
14.6.1. CleanroomClassification and Current Standards
14.6.2. Advantages ofModular Cleanrooms
14.6.3. Regulationsand Standards Concerning Modular Cleanroom Construction
14.7. ModularCleanroom Providers
14.7.1. Distributionby Industry Served
14.7.2. Distributionby Geography
14.7.3. Type ofModular Cleanrooms Offered
15. CASE STUDY:TECHNOLOGY AND EQUIPMENT PROVIDERS
15.1. ChapterOverview
15.2. Types of ContinuousManufacturing Technologies
15.3. Equipmentand Technologies for Continuous Manufacturing Small Molecules and Biologics
15.3.1. ContinuousBlending and Mixing Equipment
15.3.2. ContinuousGranulating Equipment
15.3.3. ContinuousDrying Equipment
15.3.4. ContinuousCompression Equipment
15.3.5. ContinuousCoating Equipment
15.3.6. ContinuousFiltration, Continuous Distillation and Continuous Centrifugation Equipment
15.3.7. ContinuousChromatography Equipment
15.3.8. ContinuousReactors / Bioreactors
15.3.9. Full LineContinuous Platforms
15.3.10. Process Analytical Technologies
15.3.11. Other Technologies
15.4. LogoLandscape: Analysis of Technology Providers by Number and Type of Equipment
16. CASE STUDY: ROADMAP FOR THE ADOPTION OFCONTINUOUS MANUFACTURING PROCESSES
16.1. ChapterOverview
16.2. KeyStrategies for the Adoption of Continuous Manufacturing Processes
16.2. 1. Phase I:Process Development and Implementation
16.2. 2. Phase II:Equipment / Technology Development and Installation
16.2. 3. Phase III:Facility / Plant Development and Establishment
16.2. 4. Phase IV:Product Development and Manufacturing
17. MARKETFORECAST AND OPPORTUNITY ANALYSIS
17.1. ChapterOverview
17.2. ForecastMethodology and Key Assumptions
17.3. Overall,Continuous Manufacturing Market, 2020-2030
17.3.1. ContinuousManufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030
17.3.2. ContinuousManufacturing Market: Distribution by Scale of Operation, 2020-2030
17.3.3. Continuous ManufacturingMarket: Distribution by Type of Drug Molecule, 2020-2030
17.3.4. Continuous Manufacturing Market: Distributionby Type of Continuous Manufacturing Related Service, 2020-2030
17.3.5. ContinuousManufacturing Market: Distribution by Type of Dosage Form, 2020-2030
17.3.6. ContinuousManufacturing Market: Distribution by Key Geographical Regions, 2020-2030
17.4. ContinuousManufacturing Market for Small Molecule, 2020-2030
17.4.1. Distributionby Purpose of Manufacturing, 2020-2030
17.4.2. Distributionby Scale of Operation, 2020-2030
17.4.3. Distributionby Type of Continuous Manufacturing Related Service, 2020-2030
17.4.4. Distributionby Key Geographical Regions, 2020-2030
17.5. ContinuousManufacturing Market for Biologic, 2020-2030
17.5.1. Distributionby Purpose of Manufacturing, 2020-2030
17.5.2. Distributionby Scale of Operation, 2020-2030
17.5.3. Distributionby Type of Continuous Manufacturing Related Service, 2020-2030
17.5.4. Distributionby Key Geographical Regions, 2020-2030
18. CONCLUSION
18.1. ChapterOverview
18.2. KeyTakeaways
19. EXECUTIVEINSIGHTS
19.1. ChapterOverview
19.2. Zaiput FlowTechnologies
19.2.1. CompanySnapshot
19.2.2. InterviewTranscript: Andrea Adamo, Founder and Chief Executive Officer
19.3. CONTINUUSPharmaceuticals
19.3.1. CompanySnapshot
19.3.2. InterviewTranscript: Bayan Takizawa, Co-Founder and Chief Business Officer
19.4. SnapdragonChemistry
19.4.1. CompanySnapshot
19.4.2. InterviewTranscript: Eric Fang, Chief Scientific Officer
19.5. EnzeneBiosciences
19.5.1. CompanySnapshot
19.5.2. InterviewTranscript: Himanshu Gadgil, Director and Chief Scientific Officer
19.6. Pfizer
19.6.1. CompanySnapshot
19.6.2. InterviewTranscript: Nick Thomson, Senior Director Chemical Research and Development
19.7. Universityof Strathclyde
19.7.1. CompanySnapshot
19.7.2. InterviewTranscript: Ian Houson, Technical Project Manager
20. APPENDIX 1:TABULATED DATA
21. APPENDIX 2:LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
